Sanofi and Regeneron added in a statement that if Dupixent won
approval from the FDA, it would become the first biologic medicine
available in the United States for such children.
The FDA is due to make its decision on May 26.
(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)
[© 2020 Thomson Reuters. All rights
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.